Probiotics for ulcerative colitis: mechanisms, therapeutic advances, and emerging strategies

TL;DR

This review explores how probiotics and related strategies can help treat ulcerative colitis by improving gut health and reducing inflammation.

Contribution

The paper highlights novel probiotic-based strategies, such as postbiotics and targeted delivery systems, for treating ulcerative colitis.

Findings

Probiotics help treat UC by rebalancing gut microbiota and restoring intestinal barriers.

New strategies like postbiotics and engineered delivery systems improve probiotic efficacy.

Combining probiotics with traditional Chinese medicine and fecal microbiota transplantation shows promise.

Abstract

Ulcerative colitis (UC) is a chronic, relapsing inflammatory bowel disease with a rising global incidence. Existing therapies are often limited by suboptimal efficacy and frequent relapse. Gut microbiota dysbiosis is central to UC pathogenesis, providing a rationale for probiotic-based, microbiota-targeted interventions. This review synthesizes evidence that probiotics mitigate UC through multiple synergistic mechanisms: competitive exclusion to rebalance the microbiota, upregulation of tight junction proteins to restore the intestinal barrier, and bidirectional immunomodulation to restrain excessive inflammation. These mechanisms are supported by extensive preclinical and clinical data. Research is increasingly moving beyond conventional live formulations toward defined postbiotics, probiotic–traditional Chinese medicine combinations, targeted delivery systems engineered with smart materials, and fecal microbiota transplantation. These strategies seek to overcome limitations such as low bacterial viability and poor targeting, thereby improving therapeutic precision and efficacy. Collectively, probiotics and their derivative approaches offer promising adjunct or alternative options for the clinical management of UC via multitarget modulation of the intestinal microenvironment.

Figures